Navigating Today and Shaping Tomorrow in ISM: Personalized Strategies With Current and Emerging KIT Inhibitors

Navigating Today and Shaping Tomorrow in ISM: Personalized Strategies With Current and Emerging KIT Inhibitors

From CME by ReachMD

March 31, 2026 · 14 min

About this episode

The episode discusses the role of KIT-targeted TKIs in treating indolent systemic mastocytosis, featuring expert insights on current and emerging therapies.

Faculty: Mariana C. Castells, MD, PhD Faculty: Tsewang Tashi, MD This online educational activity explores the evolving role of KIT-targeted tyrosine kinase inhibitors (TKIs) in indolent systemic mastocytosis (ISM). Expert faculty discuss pivotal clinical data supporting the approval of avapritinib, a potent TKI that targets KIT D816V, in patients with ISM. They also highlight emerging clinical evidence on next-generation KIT TKIs, such as elenestinib and bezuclastinib, that are designed for enhanced selectivity and minimal brain penetration. Finally, faculty discuss how these agents may be sequenced and integrated into a personalized, multidisciplinary treatment approach aimed at durable symptom control and improved quality of life for patients with ISM.

People in this episode

Guests: Mariana C. Castells, MD, PhD, Tsewang Tashi, MD

Topics covered

  • KIT-targeted tyrosine kinase inhibitors
  • indolent systemic mastocytosis
  • personalized treatment strategies
  • clinical data
  • emerging clinical evidence
  • multidisciplinary treatment approach

Keywords

  • KIT inhibitors
  • tyrosine kinase inhibitors
  • systemic mastocytosis
  • avapritinib
  • elenestinib
  • bezuclastinib
  • personalized medicine
  • clinical evidence

Mentioned in this episode

Organizations: ReachMD

Products: avapritinib, elenestinib, bezuclastinib

More episodes of CME

Explore listener stats, chart rankings, contacts and more on the CME podcast page.